Serif Biomedicines raised $50 million to build a Modified DNA therapeutic platform with initial programs focused on genetically defined rare diseases and immune reprogramming, representing a first-in-class approach designed to combine the durability of gene therapy with the programmability and scalability of mRNA medicines.
